DAM
NBIX icon

DLD Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

DLD Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-103,800
Closed -$6.36M – 93
2017
Q3 		$6.36M Buy
+103,800
New +$5.48M 0.63% 28

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DLD Asset Management's NBIX Position: Q4 2017 in Review

DLD Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 103,800 shares — an estimated $6.36M sold.

DLD Asset Management first reported a position in NBIX in Q3 2017 and held it in 1 quarter. The position peaked at $6.36M in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

  • DLD Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
  • DLD Asset Management sold 103,800 Neurocrine Biosciences shares in Q4 2017, an estimated $6.36M.
  • DLD Asset Management first reported a position in Neurocrine Biosciences in Q3 2017 and held it in 1 quarter.
  • DLD Asset Management's Neurocrine Biosciences position peaked at $6.36M in Q3 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on DLD Asset Management's 13F filing for Q4 2017, filed 12 Feb 2018.